MedTrace Logo

Study on Allopregnanolone and Depression in Women Across the Menopause Transition

NCT06238700 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-14

No results posted yet for this study

Summary

This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.

Conditions

Interventions

DIETARY_SUPPLEMENT

pregnenolone

Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.

OTHER

placebo

Placebo pills are identical-appearing capsules containing cellulose

Sponsors & Collaborators

Principal Investigators

  • Katherine Burdick, PhD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-14
Primary Completion
2027-07-31
Completion
2027-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238700 on ClinicalTrials.gov